Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings

Astrazeneca (AZN) reported $15.5 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 4.1%. EPS of $1.06 for the same period compares to $2.10 a year ago.The reported revenue represents a surprise of -1.74% over the Zacks Consensus Estimate of $15.78 billion. With the consensus EPS estimate being $2.18, the EPS surprise was -51.38%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Astrazeneca performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:BioPharmaceuticals- R&I- Fasenra- U.S.: $309 million compared to the $339.58 million average estimate based on three analysts. The reported number represents a change of +3.3% year over year.BioPharmaceuticals- R&I- Other- U.S.: $8 million compared to the $93.36 million average estimate based on three analysts. The reported number represents a change of -92% year over year.BioPharmaceuticals- R&I- Breztri- Europe: $55 million versus $53.5 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +31% change.BioPharmaceuticals- R&I- Breztri- U.S.: $153 million versus the three-analyst average estimate of $174.61 million. The reported number represents a year-over-year change of +2.7%.Alliance Revenue- Total: $959 million compared to the $916.42 million average estimate based on four analysts. The reported number represents a change of +34.3% year over year.Collaboration Revenue- Total: $6 million versus $173.65 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -99.3% change.BioPharmaceuticals- R&I- Fasenra- Emerging Markets: $36 million compared to the $30.13 million average estimate based on three analysts. The reported number represents a change of +56.5% year over year.BioPharmaceuticals- R&I- Breztri- Emerging Markets: $59 million versus the three-analyst average estimate of $81.3 million. The reported number represents a year-over-year change of +31.1%.BioPharmaceuticals- R&I- Tezspire- Emerging Markets: $16 million versus the three-analyst average estimate of $8.47 million. The reported number represents a year-over-year change of +300%.BioPharmaceuticals- R&I- Pulmicort- Emerging Markets: $134 million versus the three-analyst average estimate of $77.1 million. The reported number represents a year-over-year change of -5%.BioPharmaceuticals- R&I- Others- Emerging Markets: $38 million versus $41.83 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -5% change.BioPharmaceuticals- R&I- Emerging Markets: $468 million versus the three-analyst average estimate of $402.77 million. The reported number represents a year-over-year change of +14.7%.View all Key Company Metrics for Astrazeneca here>>>Shares of Astrazeneca have returned +0.4% over the past month versus the Zacks S&P 500 composite's no change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Just Released: Zacks Top 10 Stocks for 2026Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks